- Result Patterns and Characteristics of HBeAg and HBV DNA in Patients with Chronic Hepatitis B
-
Choi EJ, Kim JH, Han MS
- KMID: 2458680
- Lab Med Online.
- 2019 Oct;9(4):210-217.
- doi: 10.3343/lmo.2019.9.4.210
BACKGROUND: Discrepancies in the results between hepatitis B e-antigen (HBeAg) and hepatitis B virus (HBV) DNA levels pose difficulties in the management of chronic hepatitis B (CHB). This study aims... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend
-
Wong GL
- KMID: 2417057
- Clin Mol Hepatol.
- 2018 Jun;24(2):108-113.
- doi: 10.3350/cmh.2017.0068
The natural history of chronic hepatitis B (CHB) is complex and may run through different immune phases that may overlap. In particulars, the immune-tolerant phase is the most interesting and... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
-
Kim HJ, Cho YK, Jeon WK, Kim BI
- KMID: 2406041
- Clin Mol Hepatol.
- 2017 Dec;23(4):323-330.
- doi: 10.3350/cmh.2017.0005
BACKGROUND/AIMS: Clinical characteristics of patients with chronic hepatitis B (CHB) who developed genotypic resistance to entecavir (ETV) were compared to those without resistance. METHODS: Two hundred fifty eight CHB patients who... -
- CITED
-
- Close
- SHARE
-
- Close
- Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B
-
Wi CI, Kim WR, Gross JB, Stadheim L, Poterucha
- KMID: 2412051
- Gut Liver.
- 2016 Jul;10(4):611-616.
- doi: 10.5009/gnl14256
BACKGROUND/AIMS: Despite the potent suppression of the hepatitis B virus with modern antiviral agents, only a minority of HBeAg-positive patients achieve hepatitis B e antigen seroconversion. We aimed to explore... -
- CITED
-
- Close
- SHARE
-
- Close
- The effect of low dose corticosteroid therapy on viral reactivation in patients with chronic hepatitis B virus infection
-
Lee HI, Gwak GY, Park MK, Suh HJ, Lee JH, Koh KC, Paik SW, Yoo BC
- KMID: 2256193
- Korean J Med.
- 2008 Jun;74(6):619-623.
BACKGROUND/AIMS: We investigated the effect of low dose corticosteroid therapy on HBV reactivation in patients with chronic HBV infection. METHODS: From August 1998 to March 2007, the HBsAg-positive patients who received... -
- CITED
-
- Close
- SHARE
-
- Close
- Lamivudine Therapy for Korean Children with Chronic Hepatitis B
-
Koh H, Baek SY, Chung KS
- KMID: 1786205
- Yonsei Med J.
- 2007 Dec;48(6):927-933.
- doi: 10.3349/ymj.2007.48.6.927
PURPOSE: Lamivudine is known to be very effective in suppressing hepatitis B virus replication and virus induced necroinflammation. The aim of this study was to evaluate lamivudine therapy efficacy,... -
- CITED
-
- Close
- SHARE
-
- Close
- Change of HBV DNA Level as a Predictor of HBeAg Loss after Lamivudine Treatment
-
Jung JK, Lee CH, Kim EY, Jung JT, Choi JH, Han JM, Jin MI, Cho JY, Kim BS, Shin IH
- KMID: 1776827
- Korean J Hepatol.
- 2007 Dec;13(4):513-520.
- doi: 10.3350/kjhep.2007.13.4.513
BACKGROUND AND AIMS: Lamivudine is an effective, safe therapeutic agent for the treatment of chronic hepatitis B. The aim of this study was to investigate whether early suppression of... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term Outcome after Prophylactic Lamivudine Treatment on Hepatitis B Virus Reactivation in Non-Hodgkin's Lymphoma
-
Kim JS, Hahn JS, Park SY, Kim YR, Park IH, Lee CK, Cheong JW, Lee ST, Min YH
- KMID: 1093527
- Yonsei Med J.
- 2007 Feb;48(1):78-89.
- doi: 10.3349/ymj.2007.48.1.78
Hepatitis B virus (HBV) reactivation is the frequent complication after cytotoxic chemotherapy in HBsAg-positive non-Hodgkin's lymphoma (NHL) patients. Pre-chemotherapy viral load may be a risk factor and HBeAg-positive status is... -
- CITED
-
- Close
- SHARE
-
- Close
- HBV-specific CD8+ T cells for Sustained HBeAg Seroconversion after Lamivudine Therapy
-
Lee CK, Han KH, Suh JH, Cho YS, Won SY, Chon CY, Moon YM, Park IS
- KMID: 760578
- Korean J Hepatol.
- 2005 Mar;11(1):34-42.
BACKGROUND/AIMS: Viral suppression of the hepatitis B virus (HBV) can be induced by lamivudine, but the relapse seen in many patients after cessation of lamivudine therapy is troublesome. We... -
- CITED
-
- Close
- SHARE
-
- Close
- Analysis of Clinical Features and Hepatitis B Virus DNA Level in the Concomitant Cases of Hepatitis B Surface Antigen and Antibody
-
Jeon BR, Park R, Shin JW, Choi TY, Shin HB, Lee YK, Choi YJ, Kim HJ, Ahn JY
- KMID: 1892723
- Korean J Clin Microbiol.
- 2004 Sep;7(2):105-110.
BACKGROUND: After an infection with HBV, HBsAg is the first virologic marker detectable in the serum. If anti-HBs against 'a'determinant of HBsAg appears, HBsAg will disappear and the patients will... -
- CITED
-
- Close
- SHARE
-
- Close
- Relevancy between Liver Injury, Serum HBV-DNA, and Intrahepatic HBcAg in Young Male Chronic HBV Carriers
-
Kim TH, Kim YS, Yeom JJ, Cho EY, Kim HS, Kim HC, Park DS, Cho JH, Yoon GJ, Moon HB
- KMID: 1113322
- Korean J Gastroenterol.
- 2004 Aug;44(2):84-92.
BACKGROUND/AIMS: Although the viral load is correlated with HBcAg, liver injury was not correlated to viral load in HBeAg positive patient. We aimed to study the inter-relationship of clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Etiology and Clinical Consequence of Spontaneous Acute Exacerbation of Chronic Hepatitis B
-
Chae MJ, Kim BH, Jeong KH, Kim NH, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R
- KMID: 760537
- Korean J Hepatol.
- 2004 Jun;10(2):99-107.
BACKGROUND/AIMS: Acute exacerbation (AE) of chronic hepatitis B (CHB) can occur spontaneously, and may be followed by HBeAg clearance. HBeAg seroconversion often coincides with the normalization of liver biochemical... -
- CITED
-
- Close
- SHARE
-
- Close
- Pretreatment ALT Level and Histologic Activity as Predictors of HBeAg Loss in Lamivudine Treatment for Chronic Hepatitis B
-
Kweon YO, Kang KH
- KMID: 760529
- Korean J Hepatol.
- 2004 Mar;10(1):31-41.
BACKGROUND/AIMS: Lamivudine is a potent inhibitor of hepatitis B virus replication, but an increased incidence of YMDD mutation may be associated with its long term use. Thus, the decision... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Factors and Clinical Outcome of Viral Breakthrough during Lamivudine Treatment for Chronic Hepatitis B Infection
-
Park NH, Shin JW, Park JH, Bang SJ, Kim DH, Joo KR, Kim DH
- KMID: 1085302
- Korean J Hepatol.
- 2003 Dec;9(4):293-303.
BACKGROUND/AIMS: Long-term treatment with lamivudine causes breakthrough, but the clinical course after lamivudine breakthrough is not well known. The aims of this study were to evaluate the clinical course... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum ALT and HBV DNA Levels in Patients with HBeAg-Negative Chronic Hepatitis B
-
Kim KH, Na IH, Cha JM, Cho YK, Park SY, Kim HP, Song CS, Heo J, Cho M
- KMID: 1085301
- Korean J Hepatol.
- 2003 Dec;9(4):284-292.
BACKGROUND/AIMS: HBeAg-negative chronic hepatitis B (CHB) has a poor long-term prognosis. Since no precise clinically relevant HBV thresholds are known in HBeAg-negative CHB, the decision to treat is difficult.... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Factors and Efficacy of Lamivudine Treatment in Chronic Hepatitis B Infection
-
Park NH, Shin JW, Park JH, Bang SJ, Kim DH, Joo KR, Kim DH
- KMID: 772561
- Korean J Gastroenterol.
- 2003 Oct;42(4):303-312.
BACKGROUND/AIMS: Lamivudine, an oral nucleoside analogue, effectively suppresses hepatitis B virus (HBV) replications and improves liver enzymes as well as liver histology. The aim of this study was to evaluate... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical and Histologic Evaluation on HBeAg Positive and Negative Chronic Hepatitis B in Young Adults
-
Jung PJ, Park CH, Noh DY, Joo YE, Choi SK, Rew JS, Kim SJ
- KMID: 2274933
- Chonnam Med J.
- 2003 Jun;39(2):73-78.
It has recently been reported was active viral replication and severe liver damage may persist in HBeAg negative chronic hepatitis B. This study was aimed to compare clinical, biochemical, and... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Lamivudine in Patients with Hepatitis B e Antigen-Negative Chronic Liver Diseases
-
Jeong ID, Park NH, Kim BC, Park JH, Seo KW, Kim DH, Joo KR, Kim DH
- KMID: 863140
- Korean J Hepatol.
- 2003 Jun;9(2):69-78.
BACKGROUND/AIMS: Lamivudine therapy is effective in inhibiting HBV replications in patients with HBeAg-negative chronic liver disease. However, the sustained response rate appears to be particularly poor, because the vast... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum Hepatitis B Virus DNA Quantitative Analysis Using Polymerase Chain Reaction in Patients with Chronic Hepatits B Virus Infection
-
Oh SH, Kim HH, Heo J, Cho M, Chang CL, Lee EY, Son HC
- KMID: 1866519
- Korean J Lab Med.
- 2003 Feb;23(1):39-44.
BACKGROUND: The treatment using more potent antiviral agents for the hepatitis B virus (HBV) infection has been performed widely and a highly sensitive quantification method using the polymerase chain reaction... -
- CITED
-
- Close
- SHARE
-
- Close
- Viral Breakthrough in HBeAg-Negative Chronic Hepatitis B Patients Receiving Lamivudine Therapy
-
Chang YJ, Yim JY, Cho NY, Choi CW, Baek SJ, Ahn SH, Choi DW, Kwon YD, Kim SS, Kwon OS, Kim JH, Yeon JE, Song JW, Byun KS, Lee CH
- KMID: 863115
- Korean J Hepatol.
- 2002 Dec;8(4):397-404.
BACKGROUND/AIMS: Long-term efficacy and the rate of viral breakthrough in patients with HBeAg- negative chronic hepatitis B receiving lamivudine therapy is uncertain. This study was conducted to determine the... -
- CITED
-
- Close
- SHARE
-
- Close
